Jacob Chacko - Net Worth and Insider Trading

Jacob Chacko Net Worth

The estimated net worth of Jacob Chacko is at least $8 Million dollars as of 2024-11-05. Jacob Chacko is the PRESIDENT AND CEO of ORIC Pharmaceuticals Inc and owns about 728,544 shares of ORIC Pharmaceuticals Inc (ORIC) stock worth over $7 Million. Jacob Chacko is the CFO of Ignyta Inc and owns about 42,838 shares of Ignyta Inc (RXDX) stock worth over $1 Million. Jacob Chacko is also the Director of 4D Molecular Therapeutics Inc and owns about 0 shares of 4D Molecular Therapeutics Inc (FDMT) stock worth over $0. Details can be seen in Jacob Chacko's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jacob Chacko has not made any transactions after 2024-03-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Jacob Chacko

To

Jacob Chacko Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jacob Chacko owns 4 companies in total, including Turning Point Therapeutics Inc (TPTX) , ORIC Pharmaceuticals Inc (ORIC) , and Ignyta Inc (RXDX) among others .

Click here to see the complete history of Jacob Chacko’s form 4 insider trades.

Insider Ownership Summary of Jacob Chacko

Ticker Comapny Transaction Date Type of Owner
TPTX Turning Point Therapeutics Inc 2019-04-16 director
ORIC ORIC Pharmaceuticals Inc 2024-03-06 director & President and CEO
RXDX Ignyta Inc 2018-02-08 Chief Financial Officer
LIMIT LIMIT 2023-04-21 director

Jacob Chacko Latest Holdings Summary

Jacob Chacko currently owns a total of 3 stocks. Among these stocks, Jacob Chacko owns 728,544 shares of ORIC Pharmaceuticals Inc (ORIC) as of March 6, 2024, with a value of $7 Million and a weighting of 85.93%. Jacob Chacko owns 42,838 shares of Ignyta Inc (RXDX) as of March 17, 2016, with a value of $1 Million and a weighting of 14.07%. Jacob Chacko also owns 0 shares of 4D Molecular Therapeutics Inc (FDMT) as of April 21, 2023, with a value of $0 and a weighting of 0%.

Latest Holdings of Jacob Chacko

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ORIC ORIC Pharmaceuticals Inc 2024-03-06 728,544 9.68 7,052,306
RXDX Ignyta Inc 2016-03-17 42,838 26.95 1,154,484
FDMT 4D Molecular Therapeutics Inc 2023-04-21 0 8.35 0

Holding Weightings of Jacob Chacko


Jacob Chacko Form 4 Trading Tracker

According to the SEC Form 4 filings, Jacob Chacko has made a total of 15 transactions in ORIC Pharmaceuticals Inc (ORIC) over the past 5 years, including 2 buys and 13 sells. The most-recent trade in ORIC Pharmaceuticals Inc is the sale of 40,000 shares on March 6, 2024, which brought Jacob Chacko around $648,400.

According to the SEC Form 4 filings, Jacob Chacko has made a total of 0 transactions in Ignyta Inc (RXDX) over the past 5 years. The most-recent trade in Ignyta Inc is the acquisition of 10,000 shares on March 17, 2016, which cost Jacob Chacko around $56,400.

According to the SEC Form 4 filings, Jacob Chacko has made a total of 1 transactions in 4D Molecular Therapeutics Inc (FDMT) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in 4D Molecular Therapeutics Inc is the sale of 5,000 shares on April 21, 2023, which brought Jacob Chacko around $100,250.

Insider Trading History of Jacob Chacko

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jacob Chacko Trading Performance

GuruFocus tracks the stock performance after each of Jacob Chacko's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jacob Chacko is 2.89%. GuruFocus also compares Jacob Chacko's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jacob Chacko within 3 months outperforms 3 times out of 5 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jacob Chacko's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jacob Chacko

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
3 out of 5 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 21.88 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 26.56 LIMIT LIMIT LIMIT LIMIT LIMIT

Jacob Chacko Ownership Network

Ownership Network List of Jacob Chacko

No Data

Ownership Network Relation of Jacob Chacko

Insider Network Chart

Jacob Chacko Owned Company Details

What does Turning Point Therapeutics Inc do?

Who are the key executives at Turning Point Therapeutics Inc?

Jacob Chacko is the director of Turning Point Therapeutics Inc. Other key executives at Turning Point Therapeutics Inc include EVP & Chief Financial Officer Paolo Tombesi , SVP & Chief Commercial Officer Steve M Sabus , and SVP & General Counsel Brian Sun .

Turning Point Therapeutics Inc (TPTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Turning Point Therapeutics Inc (TPTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Turning Point Therapeutics Inc (TPTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Turning Point Therapeutics Inc (TPTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Turning Point Therapeutics Inc Insider Transactions

No Available Data

Jacob Chacko Mailing Address

Above is the net worth, insider trading, and ownership report for Jacob Chacko. You might contact Jacob Chacko via mailing address: C/o Ignyta, Inc., 11095 Flintkote Ave., Suite D, San Diego Ca 92121.